Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Volkmann

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|August 21, 2019
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung DiseaseGrace Hyun J Kim, Donald P Tashkin, Pechin Lo, et al.
Arthritis Care & Research|March 14, 2022
Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis CohortsNancy Wareing, Vishnu Mohan, Rana Taherian, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
CHEST Pulmonary|September 8, 2025
Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative StudyAngela Kaczorowski-Worthley, Dinesh Pal Mudaranthakam, Janell Reichuber, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Arthritis Care & Research|March 2, 2010
Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosusElizabeth R Volkmann, Jennifer M Grossman, Lori J Sahakian, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung DiseaseMasatoshi Hotta, Grace Hyun J Kim, Vilasinee Rerkpichaisuth, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Arthritis & Rheumatology (Hoboken, N.J.)|August 21, 2019
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung DiseaseGrace Hyun J Kim, Donald P Tashkin, Pechin Lo, et al.
Arthritis Care & Research|March 14, 2022
Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis CohortsNancy Wareing, Vishnu Mohan, Rana Taherian, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
CHEST Pulmonary|September 8, 2025
Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative StudyAngela Kaczorowski-Worthley, Dinesh Pal Mudaranthakam, Janell Reichuber, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Arthritis Care & Research|March 2, 2010
Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosusElizabeth R Volkmann, Jennifer M Grossman, Lori J Sahakian, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung DiseaseMasatoshi Hotta, Grace Hyun J Kim, Vilasinee Rerkpichaisuth, et al.
Pageof 20